These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Bazedoxifene: a new selective estrogen receptor modulator for postmenopausal osteoporosis. Genant HK Menopause Int; 2011 Jun; 17(2):44-9. PubMed ID: 21693498 [TBL] [Abstract][Full Text] [Related]
24. Who will benefit from treatment with selective estrogen receptor modulators (SERMs)? Sambrook P Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):975-81. PubMed ID: 16301191 [TBL] [Abstract][Full Text] [Related]
25. [Raloxifene (Evista) in the treatment of postmenopausal osteoporosis--the profile of the patient]. Kastelan D; Korsić M Reumatizam; 2005; 52(2):67-70. PubMed ID: 16689133 [TBL] [Abstract][Full Text] [Related]
26. Raloxifene and its role in breast cancer prevention. Eng-Wong J; Zujewski JA Expert Rev Anticancer Ther; 2004 Aug; 4(4):523-32. PubMed ID: 15270657 [TBL] [Abstract][Full Text] [Related]
28. Raloxifene: a selective estrogen receptor modulator. Scott JA; Da Camara CC; Early JE Am Fam Physician; 1999 Sep; 60(4):1131-9. PubMed ID: 10507743 [TBL] [Abstract][Full Text] [Related]
29. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk. Lippman ME; Cummings SR; Disch DP; Mershon JL; Dowsett SA; Cauley JA; Martino S Clin Cancer Res; 2006 Sep; 12(17):5242-7. PubMed ID: 16951244 [TBL] [Abstract][Full Text] [Related]
30. [Therapeutic agents for disorders of bone and calcium metabolism: Bazedoxifene]. Chaki O Clin Calcium; 2007 Jan; 17(1):30-5. PubMed ID: 17211091 [TBL] [Abstract][Full Text] [Related]
31. Safety assessment of raloxifene over eight years in a clinical trial setting. Martino S; Disch D; Dowsett SA; Keech CA; Mershon JL Curr Med Res Opin; 2005 Sep; 21(9):1441-52. PubMed ID: 16197663 [TBL] [Abstract][Full Text] [Related]
32. Chemoprevention of breast cancer. O'Regan RM Cancer Treat Res; 2000; 103():183-207. PubMed ID: 10948447 [No Abstract] [Full Text] [Related]
33. The use of raloxifene in osteoporosis treatment. D'Amelio P; Isaia GC Expert Opin Pharmacother; 2013 May; 14(7):949-56. PubMed ID: 23521229 [TBL] [Abstract][Full Text] [Related]
35. [Effects of SERMs on bone health. Raloxifene effects on breast cancer and cardiovascular events]. Inoue D Clin Calcium; 2010 Mar; 20(3):331-8. PubMed ID: 20190362 [TBL] [Abstract][Full Text] [Related]
36. [Effects of raloxifene on bone loss and fracture risk in the menopausal woman]. Vignot E; Meunier PJ Contracept Fertil Sex; 1999 Dec; 27(12):858-60. PubMed ID: 10676043 [TBL] [Abstract][Full Text] [Related]
37. Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis. Stepan JJ; Alenfeld F; Boivin G; Feyen JH; Lakatos P Endocr Regul; 2003 Dec; 37(4):225-38. PubMed ID: 15106819 [TBL] [Abstract][Full Text] [Related]
38. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis. Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083 [TBL] [Abstract][Full Text] [Related]
39. Raloxifene, tamoxifen and vascular tone. Leung FP; Tsang SY; Wong CM; Yung LM; Chan YC; Leung HS; Yao X; Huang Y Clin Exp Pharmacol Physiol; 2007 Aug; 34(8):809-13. PubMed ID: 17600563 [TBL] [Abstract][Full Text] [Related]